Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Pfizer Inc. (NYSE:PFE) announced today that additional data from several clinical studies of Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), which is being held Oct. 20-23, 2011, in Boston, Mass. The data from these studies provide support for the pending regulatory applications for the use of Prevnar 13 in adults 50 years and older to help prevent pneumococcal disease.

More About the Prevnar 13 Adult Clinical Studies

  • Poster Title: A Phase 3, Open-label Trial Evaluating the Safety and Immunogenicity of a Subsequent Dose of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Elderly Adults Who Received PCV13 Followed by 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) in a Prior Trial

Presentation #664, Pneumococcal Vaccines Poster Session, Friday, October 21, 12:15-2:15 p.m. (ET)

  • Poster Title: A Phase 3, Randomized, Active-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Sequential Administration of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and 23-valent Pneumococcal Polysaccharide Vaccine (PPSV23) Administered at 1-Year Intervals in PPSV23-naïve Adults 60-64 Years of Age

Presentation #665, Pneumococcal Vaccines Poster Session, Friday, October 21, 12:15-2:15 p.m. (ET)

  • Poster Title: 13-valent Pneumococcal Conjugate Vaccine (PCV13) Enhances the Response to Subsequent PCV13 and 23-valent Pneumococcal Polysaccharide (PPSV23) Vaccinations in Adults 50 Years and Older

Presentation #LB-3, Late Breaker Poster Session, Saturday, October 22, 11:45 a.m.-1:45 p.m. (ET)

Source:

Pfizer Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Comparing SARS-CoV-2 Omicron BA.2 and BA.5 vaccine breakthrough infections